acut
respiratori
distress
syndrom
present
hypoxia
bilater
pulmonari
infi
ltrate
chest
imag
absenc
heart
failur
suffi
cient
account
clinic
state
manag
larg
support
focus
protect
mechan
ventil
avoid
fl
uid
overload
patient
sever
hypoxaemia
manag
earli
shortterm
use
neuromuscular
blockad
prone
posit
ventil
extracorpor
membran
oxygen
use
inhal
nitric
oxid
rare
indic
agonist
late
corticosteroid
avoid
ortal
remain
approxim
acut
respiratori
distress
syndrom
form
noncardiogen
pulmonari
oedema
due
alveolar
injuri
secondari
infl
ammatori
process
either
pulmonari
system
origin
syndrom
present
acut
hypoxaemia
bilater
pulmonari
infi
ltrate
chest
imag
wholli
due
heart
failur
syndrom
characteris
presenc
sever
criteria
sinc
origin
descript
ashbaugh
colleagu
four
defi
nition
use
determin
presenc
acut
respiratori
distress
syndrom
tabl
american
european
consensu
confer
defi
nition
publish
fi
rst
agre
wide
use
defi
nition
howev
numer
limit
across
four
diagnost
criteria
panel
result
european
societi
intens
care
medicin
engag
consensu
process
gener
improv
defi
nition
acut
respiratori
distress
syndrom
berlin
defi
nition
publish
valid
patient
data
basi
hypoxaemia
acut
respiratori
distress
syndrom
classifi
ed
mild
ratio
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
pao
fio
mm
hg
moder
pao
fio
mm
hg
sever
pao
fio
mm
hg
import
updat
defi
nition
stipul
minimum
posit
endexpiratori
pressur
peep
cm
h
peep
increas
oxygen
key
criterion
syndromethi
updat
establish
minimum
standard
mechan
ventil
acknowledg
acut
respiratori
distress
syndrom
diagnos
presenc
cardiac
failur
requir
new
respiratori
failur
worsen
chronic
respiratori
diseas
within
day
inclus
chest
ct
altern
form
imag
demonstr
lung
infi
ltrate
landmark
arma
studi
publish
demonstr
benefi
ts
lowtidalvolum
lowairwaypressur
ventilatori
strategi
acut
respiratori
distress
syndrom
mark
establish
lung
protect
ventil
standard
care
despit
advanc
syndrom
remain
highli
preval
lungprotect
era
estim
incid
per
patient
per
year
usa
approxim
fi
seven
europ
epidemiolog
probabl
underreport
less
develop
healthcar
system
result
resourc
limit
patient
meet
current
defi
nition
diagnosi
despit
hospit
admiss
clinic
state
similar
acut
respiratori
distress
syndrom
patient
intensivecar
unit
icu
receiv
mechan
ventil
acut
respiratori
distress
syndrom
base
control
group
surviv
randomis
control
trial
publish
past
year
day
mortal
approxim
patient
die
month
larg
comorbid
rather
residu
eff
ect
acut
respiratori
distress
syndrom
lungsaf
studi
show
syndrom
remain
common
mortal
approxim
emphasis
global
burden
although
gener
icu
survivor
reduct
healthrel
qualiti
life
full
recoveri
often
limit
acut
respiratori
distress
syndrom
mani
muscl
wast
limit
weak
neuropsychiatr
ill
includ
cognit
impair
anxieti
depress
posttraumat
stress
disord
year
icu
discharg
return
work
despit
extrapulmonari
defi
cit
respiratori
function
return
close
normal
develop
acut
respiratori
distress
syndrom
describ
set
numer
ill
injuri
broadli
class
pulmonari
system
origin
pneumonia
common
risk
factor
develop
syndrom
along
aspir
highest
associ
mortal
traumarel
ill
lowest
inappropri
administ
mechan
ventil
import
contributor
develop
worsen
acut
respiratori
distress
syndrom
ventilatorinduc
lung
injuri
occur
sever
mechan
includ
excess
lung
stretch
volutrauma
pressur
barotrauma
repetit
alveolar
open
close
caus
shear
injuri
atelectrauma
potenti
oxygen
toxic
process
also
drive
excess
system
infl
ammat
abil
induc
nonpulmonari
organ
failur
biotrauma
randomis
control
trial
critic
ill
mechan
ventil
patient
ventil
ml
rather
ml
per
kg
predict
bodyweight
associ
fi
vetim
increas
odd
develop
acut
respiratori
distress
syndrom
fi
nding
substanti
randomis
control
trial
patient
risk
pulmonari
complic
undergo
gener
anaesthesia
major
abdomin
surgeri
nonlungprotect
ventilatori
strategi
mlkg
tidal
volum
ventil
peep
compar
lungprotect
ventil
mlkg
tidal
volum
peep
cm
h
plu
recruit
manoeuvr
everi
min
lungprotect
group
fewer
major
complic
vs
rel
risk
rr
ci
requir
less
respiratori
support
day
vs
shorter
hospit
stay
vs
day
diff
erenc
day
search
potenti
gene
confer
suscept
develop
alter
outcom
acut
respiratori
distress
syndrom
methodolog
complex
genotyp
phenotyp
race
environ
injuri
therapi
interact
variabl
uncertain
way
contribut
clinic
outcom
candid
gene
associ
develop
outcom
acut
respiratori
distress
syndrom
identifi
ed
although
investig
either
larg
suffi
cientli
robust
provid
clear
answer
yet
replic
data
parenthes
murray
column
score
total
number
point
score
divid
number
categori
includ
give
murray
lung
injuri
score
score
signifi
es
lung
injuri
present
score
signifi
es
mild
moder
lung
injuri
score
greater
signifi
es
sever
lung
injuri
aeccamerican
european
consensu
confer
pao
partial
pressur
arteri
oxygen
fio
fraction
inspir
oxygen
peepposit
endexpiratori
pressur
search
genet
suscept
either
onset
worsen
syndrom
might
prove
diffi
cult
issu
specifi
citi
defi
nition
acut
respiratori
distress
syndrom
improv
phenotyp
patient
address
howev
gene
clearer
associ
acut
respiratori
distress
syndrom
ace
associ
came
promin
sever
acut
respiratori
syndrom
sar
epidem
protein
contribut
regul
pulmonari
vascular
permeabl
identifi
ed
receptor
novel
coronaviru
caus
sar
onset
primari
ill
infl
ammatori
alveolar
injuri
occur
describ
term
three
sequenti
phase
fi
gure
overlap
substanti
process
begin
exud
phase
immunecellmedi
destruct
barrier
alveolar
epithelialint
stitialendotheli
complex
allow
plasma
plasma
protein
cellular
content
success
fl
ood
interstitium
airspac
classic
acut
respiratori
distress
syndrom
recognis
neutrophildriven
diseas
howev
experiment
data
shown
alveolar
neutrophilia
occur
without
increas
alveolar
permeabl
addit
involv
cell
innat
includ
macrophag
platelet
adapt
immun
system
pathogenesi
acut
respiratori
distress
syndrom
increasingli
recognis
neutrophil
macrophag
recruit
infl
ammatori
focu
propag
initi
insult
infl
ammatori
exud
produc
physic
interact
surfact
initi
caus
dysfunct
follow
epitheli
injuri
progress
loss
surfact
product
imped
alveolar
patenc
loss
epitheli
ion
channel
impair
gener
osmot
forc
requir
return
oedema
fl
uid
interstitium
injuri
plu
develop
hyalin
membran
decreas
pulmonari
complianc
result
disrupt
gaseou
diff
usion
alveolar
vascular
damag
also
occur
increas
permeabl
coexist
alter
vasomotor
tone
vaso
con
striction
vasodil
microthrombi
pulmonari
hypertens
result
increas
right
ventricular
afterload
right
ventricular
dysfunct
exacerb
mechan
ventil
fl
uid
overload
combin
epitheli
endotheli
damag
result
worsen
ventilationperfus
mismatch
loss
hypox
pulmonari
vasocon
striction
lead
refractori
hypoxia
acut
lung
injuri
term
aecc
inconsist
use
term
acut
lung
injuri
use
refer
either
patient
mild
hypoxaemia
pao
mm
hg
umbrella
term
meet
defi
nition
acut
respiratori
distress
syndrom
includ
moder
sever
hypoxaemia
mani
clinician
fail
recognis
acut
respiratori
distress
syndrom
aeccamerican
european
consensu
confer
peepposit
endexpiratori
pressur
pao
partial
pressur
arteri
oxygen
fio
fraction
inspir
oxygen
prolif
phase
mark
attempt
recoveri
restor
type
ii
alveolar
cell
popul
subsequ
diff
erenti
type
alveolar
cell
regener
function
epitheli
layer
permit
clearanc
exud
fl
uid
interstitium
remain
debri
clear
infl
ammatori
cell
vasomotor
tone
begin
return
normal
microthrombi
clear
pulmonari
hypertens
lessen
repar
continu
shunt
reduc
lead
improv
oxygen
follow
often
slowli
recov
pulmonari
complianc
third
fi
brotic
phase
develop
inconsist
compris
failur
remov
alveolar
collagen
laid
earli
injuri
process
combin
develop
cystic
chang
limit
function
recoveri
diff
use
alveolar
damag
thought
pathognomon
patholog
fi
nding
acut
respiratori
distress
syndrom
defi
ned
presenc
hyalin
membran
detect
either
lung
biopsi
autopsi
howev
specifi
c
also
occur
absenc
criteria
acut
respiratori
distress
syndrom
mani
patent
fulfi
l
diagnost
criteria
acut
respiratori
distress
syndrom
diff
use
alveolar
damag
clinic
pattern
recognis
patient
acut
respiratori
distress
syndromeeg
pulmonari
caus
consolid
less
alveolar
collaps
interstiti
oedema
nonpulmonari
caus
sub
phenotyp
describ
classifi
ed
clinic
biolog
characterist
diff
ere
clinic
outcom
respons
treatment
hyperinfl
ammatori
phenotyp
associ
wors
metabol
acidosi
higher
vasopressor
requir
increas
mortal
better
respons
higher
peep
subphenotyp
provid
mechanist
insight
pathophysiolog
acut
respiratori
distress
syndrom
like
inform
develop
personalis
therapi
berlin
defi
nition
acut
respiratori
distress
syndrom
evolut
american
european
consensu
confer
defi
nition
tabl
recognis
numer
fl
aw
revis
defi
nition
although
improv
still
limit
sever
investig
modal
potenti
help
monitor
clinic
cours
fi
gure
sequenti
imag
via
chest
radiographi
ct
fi
gure
provid
qualit
measur
diseas
evolut
ct
also
provid
specifi
c
quantit
measur
oedema
aerat
recruit
extravascular
lung
water
refl
ect
degre
pulmonari
oedema
measur
picco
puls
contour
cardiac
output
monitor
pulsion
medic
system
feldkirchen
germani
associ
mortal
patient
acut
respiratori
distress
syndrom
similarli
lung
ultra
sonographi
fi
gure
use
estim
extravascular
lung
water
allow
diff
erenti
syndrom
cardiogen
pulmonari
oedema
pulmonari
wedg
respons
ness
unlik
er
benefi
routin
manag
neither
er
benefi
pao
fio
ratio
measur
oxygen
use
classifi
acut
respiratori
distress
syndrom
mild
moder
sever
tabl
although
easi
calcul
imperfect
measur
variabl
diff
ere
peep
tidal
volum
oxygen
indexth
product
mean
airway
pressur
fio
divid
pao
altern
pao
fio
might
superior
includ
mean
airway
pressur
refl
ect
peep
respiratori
system
complianc
help
monitor
pulmonari
mechan
although
includ
berlin
defi
nition
lack
addit
discriminatori
valu
pulmonari
dead
space
fraction
associ
mortal
acut
respiratori
distress
syndrom
odd
ratio
ci
technic
challeng
measur
frequent
use
bronchoalveolar
lavag
permit
sampl
alveolar
space
help
identifi
cation
infecti
caus
acut
respiratori
distress
syndrom
diagnosi
malign
haemorrhag
absenc
biomark
defi
ne
diagnosi
respons
therapi
prognosi
acut
respiratori
distress
syndrom
problemat
limit
progress
fi
eld
diff
ere
patholog
damag
lung
tissu
divers
way
produc
inconsist
signal
numer
injur
cell
type
signal
confound
age
comorbid
iatrogen
eff
ect
excess
fl
uid
administr
harm
ventil
mani
candid
biomark
fi
gure
investig
singl
clear
biomark
prove
diffi
cult
fi
nd
biomark
measur
blood
bronchoalveolar
lavag
fl
uid
inaccur
clinic
use
combin
biomark
could
use
identifi
specifi
c
phenotyp
patient
acut
respiratori
distress
syndrom
might
respond
diff
erenti
therapi
work
requir
confi
rm
initi
fi
nding
open
lung
biopsi
remain
gold
standard
diagnosi
diff
use
alveolar
damag
small
singlecentr
observ
studi
open
lung
biopsi
highli
select
popul
show
low
specifi
citi
clinic
diagnosi
acut
respiratori
distress
syndrom
presenc
diff
use
alveolar
damag
patient
acut
respiratori
distress
syndrom
undergo
procedur
result
alter
manag
improv
outcom
littl
noteworthi
morbid
studi
limit
select
natur
constrain
abil
examin
entir
lung
open
lung
biopsi
usual
reserv
except
case
genuin
diagnost
dilemma
poor
respons
therapi
manag
acut
respiratori
distress
syndrom
class
specifi
c
support
address
underli
caus
condit
also
necessari
fi
gure
specifi
c
measur
includ
mainten
ga
exchang
manipul
underli
pathophysiolog
support
therapi
includ
sedat
mobilis
nutrit
prophylaxi
venou
thromboembol
four
randomis
control
trial
publish
provid
mix
result
optim
tidal
volum
acut
respiratori
distress
syndrom
landmark
arma
studi
publish
ardsnet
group
tradit
ventilatori
strategi
ml
per
kg
predict
bodyweight
tidal
volum
com
binat
plateau
airway
pressur
cm
h
compar
lower
tidal
volum
ml
per
kg
predict
bodyweight
com
binat
plateau
airway
pressur
cm
h
less
mechan
ventil
patient
acut
respiratori
distress
syndrom
studi
stop
earli
despit
initi
wors
oxygen
lowtidalvolum
ventil
associ
ci
absolut
reduct
mortal
vs
signifi
cantli
ventilatorfre
day
sd
vs
importantli
less
injuri
ventil
associ
day
free
nonpulmonari
organ
failur
vs
tidal
volum
estim
predict
bodyweight
depend
height
sex
calcul
height
cm
men
height
cm
women
lungprotect
ventil
associ
improv
outcom
use
earli
cours
acut
respiratori
distress
syndrom
reduc
mortal
year
despit
adopt
volumelimit
pressurelimit
protect
ventilatori
strategi
critic
ill
mechan
ventil
patient
acut
respiratori
distress
syndrom
receiv
tidal
volum
mlkg
plateau
pressur
cm
h
less
still
expos
tidal
hyperinfl
ation
wherebi
smallerthanusu
aerat
section
lung
socal
babi
lung
receiv
largerthanusu
volum
ga
result
greater
biotrauma
fewer
ventilatorfre
day
patient
without
tidal
hyperinfl
ation
similarli
posthoc
review
ardsnet
databas
demonstr
safe
upper
limit
plateau
pressur
patient
acut
respiratori
distress
syndrom
volumelimit
pressurelimit
ventil
caus
hypercapn
acidosi
overal
clinic
eff
ect
protect
ventil
hypercapnia
uncertain
hypercapn
acidosi
could
provid
protect
eff
ect
set
hightidalvolum
ventil
benefi
cial
eff
ect
note
patient
receiv
lungprotect
ventil
peep
prevent
lung
unit
collaps
end
respiratori
cycl
benefi
cial
eff
ect
includ
mainten
function
residu
capac
improv
complianc
higher
mean
airway
pressur
result
decreas
shunt
enhanc
oxygen
reduc
atelectasi
biotrauma
advantag
weigh
eff
ect
rais
intrathorac
pressurenam
decreas
venou
return
increas
right
ventricular
afterload
numer
method
set
peep
level
describ
includ
recent
oesophag
balloon
manometri
lungprotect
era
four
randomis
control
trial
done
answer
question
whether
higher
lower
pressur
superior
suggest
higher
peep
could
benefi
cial
metaanalysi
three
trial
also
show
possibl
benefi
high
peep
set
acut
respiratori
distress
syndrom
associ
lower
inhospit
mortal
vs
rr
ci
less
requir
ment
mechan
ventil
day
hazard
ratio
hr
ci
epvent
randomis
control
trial
oesophagealballoon
manometryguid
peep
compar
use
ardsnet
peepfio
tabl
show
oesophagealguid
peep
provid
increas
oxi
genat
complianc
translat
higher
peep
cm
vs
cm
h
day
one
associ
improv
adjust
day
mortal
rr
ci
metaanalysi
includ
addit
studi
show
nonsignifi
cant
improv
day
mortal
higher
peep
pool
rr
ci
without
signifi
cantli
higher
risk
barotrauma
drive
pressur
defi
ned
diff
erenc
plateau
endexpiratori
pressur
suggest
mediat
benefi
cial
eff
ect
three
main
compon
lungprotect
ventilationnam
low
tidal
volum
low
plateau
pressur
high
peep
basi
deriv
valid
cohort
patient
recruit
nine
randomis
control
trial
amato
colleagu
report
increas
drive
pressur
cm
h
associ
increas
day
mortal
rr
ci
p
accord
statist
method
multilevel
mediat
analysi
none
three
main
compon
lungprotect
ventil
individu
associ
reduc
mortal
act
via
reduc
drive
pressur
exert
benefi
cial
eff
ect
drive
pressur
could
help
calibr
mechan
stress
deliv
ventil
function
aerat
lung
volum
although
mlkg
tidal
volum
recognis
lowtidalvolum
ventil
normal
tidal
volum
mammalian
speci
avail
function
lung
volum
fall
acut
respiratori
distress
syndrom
result
collaps
consolid
perhap
deliv
tidal
volum
also
decreas
although
evid
suggest
target
drive
pressur
prudent
whether
drive
pressur
relat
causal
outcom
remain
establish
prospect
randomis
control
trial
concept
investig
set
studi
extracorpor
carbon
dioxid
remov
facilit
verylowtidalvolum
ultraprotect
ventil
although
data
drive
pressur
post
hoc
observ
natur
necessit
confi
rmation
prospect
studi
upper
limit
drive
pressur
cm
h
could
appropri
interim
atelectat
area
lung
reexpand
applic
brief
period
sustain
high
transpulmonari
pressureusu
follow
applic
higher
level
peep
maintain
stabilis
newli
reaerat
region
three
commonli
use
recruit
manoeuvr
sigh
sustain
infl
ation
extend
sigh
brief
period
rais
intrathorac
pressur
also
imped
venou
return
right
atrium
predispos
hypotens
preclin
data
shown
diverg
eff
ect
recruit
manoeuvr
alveolar
epitheli
endotheli
function
systemat
review
base
studi
show
recruit
manoeuvr
increas
oxygen
littl
inform
longterm
eff
ect
intervent
clear
guidanc
use
procedur
avail
robust
randomis
control
trial
guid
choic
mode
mechan
ventil
author
cochran
review
summaris
three
randomis
control
trial
consist
patient
total
conclud
evid
insuffi
cient
promot
use
either
volumecontrol
pressurecontrol
ventil
airwaypressurereleas
ventil
use
abil
maintain
high
mean
airway
pressureand
thu
maintain
alveolar
recruitmentwhil
permit
spontan
ventil
unfortun
evid
base
limit
suboptimum
control
group
studi
done
concern
possibl
high
tidal
volum
mean
airway
pressur
noninvas
ventil
tri
mild
acut
respiratori
distress
syndrom
small
studi
patient
show
reduc
requir
invas
mechan
ventil
nonsignifi
cant
reduct
mortal
approach
result
temper
much
larger
metaanalysi
patient
document
failur
noninvas
ventil
almost
patient
advent
highfl
ow
nasal
oxygen
allow
simpler
toler
respiratori
support
observ
studi
patient
moder
acut
respiratori
distress
syndrom
mean
pao
fio
mm
hg
treat
highfl
ow
nasal
oxygen
requir
invas
mechan
ventil
noninvas
ventil
sever
ill
associ
increas
likelihood
treatment
failur
place
patient
prone
receiv
invas
mechan
ventil
provid
mani
physiolog
advantag
manag
refractori
hypoxaemia
includ
redistribut
consolid
dorsal
ventral
area
lung
remov
weight
heart
mediastinum
lung
improv
alveolar
ventil
shunt
reduct
increas
oxygen
reduc
pulmonari
infl
matori
cytokin
product
sever
studi
produc
confl
ict
result
effi
caci
prone
posit
ventil
acut
respiratori
distress
syndrom
although
prolong
prone
posit
associ
physiolog
improv
creasingli
recognis
studi
prone
ventil
short
durat
addit
sub
sequent
metaanalys
suggest
benefi
specifi
calli
hypoxaem
patient
receiv
lungprotect
ven
tilat
proseva
studi
design
address
shortcom
patient
sever
acut
respiratori
distress
syndrom
defi
ned
pao
less
mm
hg
ventil
fio
greater
receiv
lungprotect
ventil
randomli
assign
either
supin
posit
daili
prone
posit
session
last
least
h
prone
posit
ventil
associ
reduc
day
mortal
compar
supin
ventil
vs
p
hr
ci
addit
complic
associ
prone
posit
although
centr
involv
experienc
techniqu
magnitud
eff
ect
although
larg
predict
previou
metaanalysi
hypoxaemia
sever
acut
respiratori
distress
syndrom
might
necessit
excess
ventilatori
support
risk
develop
ventilatorinduc
lung
injuri
paralysi
remov
endogen
eff
ort
improv
respiratori
mechan
lower
oxygen
con
sumption
accursi
studi
cisatracuriumbesylateinduc
paralysi
compar
placebo
patient
earli
sever
acut
respiratori
distress
syndrom
neuromuscular
blockad
h
result
inaft
adjust
baselin
pao
fio
plateau
pressur
simplifi
ed
acut
physiolog
ii
scoresa
reduc
adjust
hr
death
day
ci
importantli
frequenc
complic
includ
icuacquir
weak
diff
er
group
although
promis
addit
larg
clinic
trial
requir
confi
rm
fi
nding
mechan
ventil
reliant
function
alveolu
gaseou
diff
usion
unabl
provid
lifesav
respiratori
support
critic
volum
alveolar
unit
fail
addit
replac
endogen
alveolar
gaseou
exchang
extracorpor
ga
exchangeeith
extracorpor
membran
oxygen
ecmo
extracorpor
carbon
dioxid
removalallow
reduct
ventilatori
set
reduc
risk
ventilatorinduc
lung
injuri
present
evid
base
intervent
spars
consist
case
seri
observ
cohort
studi
one
randomis
control
trial
cesar
studi
rather
directli
assess
ecmo
refractori
hypoxaemia
investig
compar
manag
refer
centr
manag
tertiari
centr
capabl
provid
ecmo
patient
cohort
manag
ecmo
centr
higher
rate
surviv
without
disabl
month
manag
refer
centr
vs
rr
ci
although
group
receiv
ecmo
two
observ
studi
one
australia
new
zealand
one
uk
also
show
high
rate
surviv
ecmo
patient
infl
uenza
refractori
hypoxaemia
maximum
ventilatori
support
howev
ecmo
scarc
expens
resourc
often
avail
specialist
centr
fi
gure
associ
well
recognis
complic
includ
bleed
vascular
damag
risk
interhospit
transfer
despit
widespread
grow
use
worldwid
present
absenc
level
one
evid
effi
caci
uk
ecmo
nation
commiss
servic
provid
region
centr
highfrequ
oscillatori
ventil
provis
small
tidal
volum
typic
ml
per
kg
predict
bodyweight
high
frequenc
breath
per
min
via
sever
atyp
mechan
ga
transfer
mode
ventil
also
aff
ord
separ
oxygen
depend
fio
mean
airway
pressur
carbon
dioxid
remov
activ
process
depend
pressur
amplitud
frequenc
oscil
two
larg
randomis
control
trial
canada
oscil
uk
oscar
fail
show
benefi
mode
ventil
oscil
show
harm
associ
highfrequ
oscillatori
ventil
possibl
due
high
mean
airway
pressur
gener
caus
haemo
dynam
compromis
requir
higher
dose
durat
vasopressor
addit
sedat
paralysi
past
year
statin
agonist
investig
larg
placebocontrol
phase
randomis
studi
addit
cholesterollow
eff
ect
statin
pleotrop
properti
make
attract
potenti
therapi
irish
critic
care
trial
group
studi
preclin
data
suggest
agonist
could
modifi
sever
pulmonari
mechan
increas
alveolarfl
uid
clearanc
cytoprotect
antiinfl
ammatori
properti
prompt
investig
salbutamol
potenti
therapi
acut
respiratori
distress
syndrom
uk
studi
intraven
salbutamol
given
dose
per
kg
ideal
bodyweight
per
h
trial
termin
safeti
reason
recruit
patient
plan
salbutamol
associ
increas
day
mortal
compar
placebo
vs
rr
ci
decreas
ventilatorfre
organfailurefre
day
eff
ect
possibl
mediat
cardiac
metabol
toxic
form
arrhythmia
lactic
acidosi
us
ardsnet
alta
studi
inhal
salbutamol
mg
everi
h
day
patient
stop
futil
signifi
cant
diff
erenc
activ
placebo
group
primari
outcom
ventilatorfre
day
vs
ci
diff
erenc
secondari
outcom
inhospit
mortal
vs
although
patient
shock
baselin
salbutamol
group
fewer
icufre
day
placebo
group
two
pharmacotherapi
deserv
mentioncorticosteroid
nitric
oxid
acut
respiratori
distress
syndrom
infl
ammatori
lung
injuri
use
corticosteroid
would
thu
appear
ideal
suit
abil
dampen
infl
ammat
fi
brosi
unfortun
despit
plethora
trial
inadequ
evid
make
defi
nitiv
recom
mendat
favour
use
corticosteroid
although
us
ardsnet
steroid
studi
suggest
harm
corticosteroid
therapi
start
day
onset
syndrom
nitric
oxid
inhal
pulmonari
vaso
dilat
improv
ventilationperfus
match
result
increas
oxygen
howev
increas
oxygen
translat
improv
patientcentr
outcom
nitric
oxid
associ
numer
complic
includ
renal
failur
rebound
pulmonari
hypertens
variou
antiinfl
ammatori
pathophysiolog
fi
gure
target
drug
investig
demonstr
robust
eff
ectiv
fluid
manag
acut
respiratori
distress
syndrom
form
pulmonari
oedema
thu
fl
uid
therapi
essenti
aspect
manag
fluid
excess
increasingli
link
detriment
outcom
across
spectrum
critic
ill
gener
paradigm
exist
earli
fl
uid
load
resuscit
organ
rescu
thrombosi
key
present
stage
ill
follow
fl
uid
unload
deresuscit
either
spontan
inducedaft
haemodynam
stabil
achiev
fluidinduc
lung
injuri
describ
develop
lung
injuri
intraven
fl
uid
administr
rapid
administr
salin
healthi
volunt
caus
pulmonari
interstiti
oedema
patient
sepsi
experi
decreas
oxygen
worsen
lung
injuri
score
result
fl
uid
bolu
administr
initi
resuscit
randomis
control
trial
patient
acut
respiratori
distress
syndrom
manag
lungprotect
ventil
factt
detail
algorithm
target
cardiac
fi
lling
pressur
set
haemodynam
stabil
use
comparison
liber
conserv
fl
uid
strategi
week
conserv
strategi
associ
net
neutral
fl
uid
balanc
compar
l
posit
balanc
control
arm
result
signifi
cantli
increas
oxygen
better
lung
injuri
score
ventilatorfre
icufre
day
fewer
blood
transfus
conserv
manag
group
diff
erenc
conserv
liber
strategi
primari
outcom
death
day
sd
vs
ci
diff
erenc
incid
organ
failur
followup
studi
year
howev
show
increas
incid
cognit
impair
deresuscit
group
adjust
odd
ratio
ci
small
randomis
control
trial
combin
therapi
albumin
furosemid
administr
hypoproteinaem
patient
acut
respiratori
distress
syndrom
demonstr
improv
oxygen
fl
uid
balanc
haemodynam
small
followup
studi
group
furosemid
administr
without
albumin
supplement
compar
suggest
combin
superior
furosemid
administr
alon
howev
larg
randomis
control
albio
trial
investig
examin
strategi
albumin
administr
maintain
plasma
albumin
concentr
higher
gl
patient
sepsi
septic
shock
benefi
cial
eff
ect
respiratori
sequenti
organ
failur
assess
sofa
score
associ
higher
plasma
albumin
concentr
although
specifi
ed
subgroup
analysi
done
outcom
therefor
whether
albumin
place
manag
acut
respiratori
distress
syndrom
remain
unclear
basi
avail
evid
synthet
colloid
role
manag
critic
ill
investig
eden
studi
explor
eff
ect
lowvolum
trophic
feed
day
nonmalnourish
patient
earli
acut
respiratori
distress
syndrom
despit
separ
calorifi
c
deliveri
group
roughli
kcal
per
day
vs
full
feed
kcal
per
day
neither
primari
outcom
ventilatorfre
day
vs
diff
erenc
ci
seco
ndari
outcom
day
mortal
vs
infecti
complic
diff
ere
group
full
feed
group
howev
receiv
prokinet
agent
spent
day
increas
gastric
residu
volum
vomit
constip
addit
diff
erenc
physic
cognit
function
survivor
year
abil
modul
infl
ammatori
respons
via
immunonutritioni
deliveri
immuneenhanc
dietari
agent
fi
sh
oil
glutamin
selenium
vitamin
antioxidantsha
long
potenti
target
earli
studi
suggest
benefi
especi
use
acut
respiratori
distress
syndrom
randomis
control
trial
shown
effi
caci
rang
addit
either
patient
acut
respiratori
distress
syndrom
need
gener
critic
care
omega
studi
twice
daili
use
fatti
acid
docosahexaeno
acid
eicosapentaeno
acid
acid
mixtur
antioxid
compar
use
isocalor
control
patient
earli
acut
respiratori
distress
syndrom
also
receiv
enter
nutrit
despit
eighttim
increas
plasma
fatti
acid
concentr
intervent
group
clear
signal
harm
necessit
termin
studi
includ
decreas
ventilatorfre
nonpulmonaryorganfailurefre
icufre
day
nonsignifi
cant
increas
mortal
subsequ
small
phase
studi
fi
sh
oil
patient
fail
demonstr
benefi
popul
metaanalysi
support
lack
effi
caci
associ
fi
sh
oil
supplement
patient
acut
respiratori
distress
syndrom
consensu
paper
summaris
current
nutrit
evid
support
administr
pharma
conutri
direct
compar
studi
optimum
choic
sed
depth
sedat
obtain
patient
acut
respiratori
distress
syndrom
gener
patient
lightli
sedat
emphasi
analgesia
benzodiazepin
avoid
possibl
earli
deep
sedat
mechan
ventil
patient
associ
increas
mortal
contrast
earli
mobilis
associ
improv
outcom
mechan
ventil
patient
acut
respiratori
failur
despit
promis
preclin
earli
clinic
data
larg
phase
studi
therapeut
intervent
acut
respiratori
distress
syndrom
fail
demonstr
effi
caci
mani
reason
failur
arguabl
import
limit
current
defi
nition
acut
respiratori
distress
syndrom
term
identifi
cation
patient
express
biolog
target
investig
approxim
half
patient
meet
diagnost
criteria
subsequ
undergo
postmortem
examin
pathognomon
fi
nding
diff
use
alveolar
damag
present
patient
could
mixtur
coexist
condit
posit
trial
far
improv
outcom
result
less
injuri
mechan
ventil
intervent
group
mechan
ventil
patient
risk
ventilatorinduc
lung
injuri
thu
limit
recruit
heterogen
cohort
base
defi
nition
acut
respiratori
distress
syndrom
minimis
howev
therapi
aim
specifi
c
biolog
target
investig
heterogen
assum
greater
import
reduc
abil
detect
possibl
eff
ect
issu
rais
question
whether
unsuccess
therapeut
trial
report
would
result
possibl
identifi
specifi
c
phenotyp
respons
therapi
investig
construct
trial
studi
popul
biolog
target
investig
problemat
clear
implic
evid
base
acut
respiratori
distress
syndrom
larg
reliant
american
european
consensu
confer
berlin
defi
nition
era
personalis
therapi
discoveri
biomark
panel
biomark
identifi
specifi
c
popul
also
importantli
defi
ne
respons
therapi
essenti
guidelin
ventilatori
manag
acut
respiratori
distress
syndrom
issu
scandinavian
societi
anaesthesiolog
intens
care
medicin
brazilian
associ
intens
care
medicin
brazilian
thorac
societi
guidelin
american
thorac
societi
mechan
ventil
adult
acut
respiratori
distress
syndrom
uk
intens
care
societi
manag
develop
